Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)-negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, may have efficacy in patients with MRD-negative remission.

-negative BCP-ALL (with :: indicating fusion) who had MRD-negative remission (defined as